Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Evaxion Biotech ( (EVAX) ).
Evaxion A/S reported on April 17, 2026, that new data validate the scalability of its AI-Immunology platform for designing vaccines against glioblastoma, a highly lethal brain cancer with limited treatment options. In collaboration with Duke University School of Medicine, the company identified endogenous retrovirus-derived antigens and quality neoantigens in glioblastoma tumors, suggesting a strong proof-of-concept for personalized vaccines that may overcome low mutational burden and reinforcing Evaxion’s positioning as a leader in AI-driven immuno-oncology.
The findings, which include bioinformatic profiling, vaccine design feasibility and experimental evidence of immune responses to ERV antigens, will be presented at the AACR Annual Meeting in San Diego on April 22, 2026. By opening a new, tumor-specific antigen source from the so-called dark genome, the data highlight the platform’s potential to enhance cancer vaccine efficacy and are likely to attract increased interest from scientific stakeholders and potential industry partners.
The most recent analyst rating on (EVAX) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
The score is driven primarily by improved capitalization but still-weak cash generation and profitability. Technicals are moderately favorable with improving momentum, while valuation remains limited by losses. Earnings-call commentary adds support via clear milestone roadmap, strong EVX-01 results, and runway into H2 2027, tempered by dilution/partnering execution risks.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a Copenhagen-based clinical-stage TechBio company that develops novel cancer and infectious disease vaccines using its proprietary AI-Immunology platform. The AI-driven technology is designed to decode the human immune system for rapid target discovery, drug design and development, supporting both personalized and off-the-shelf vaccine candidates addressing high unmet medical needs.
Average Trading Volume: 42,985
Technical Sentiment Signal: Sell
Current Market Cap: $34.53M
See more insights into EVAX stock on TipRanks’ Stock Analysis page.